What are the indications, dosing regimens, administration instructions, and monitoring recommendations for ursodeoxycholic acid (Ursodiol)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ursodiol (Ursodeoxycholic Acid): Clinical Indications, Dosing, and Monitoring

Primary Indications

Ursodiol is the first-line treatment for primary biliary cholangitis (PBC) at 13-15 mg/kg/day in divided doses, where it improves transplant-free survival and delays histologic progression. 1

Established Indications with Strong Evidence:

Primary Biliary Cholangitis (PBC)

  • Dosing: 13-15 mg/kg/day divided into 2-3 doses 2, 1, 3
  • Efficacy: Reduces serum bilirubin, alkaline phosphatase, and cholesterol; delays histologic progression; improves transplant-free survival 2, 1
  • Response assessment: Evaluate biochemical response at 12 months; at least two-thirds of patients should respond with near-normalization of alkaline phosphatase 4
  • Duration: Lifelong therapy, even in partial responders, as it provides sustained survival benefits 1
  • Post-transplant: Continue lifelong after liver transplantation to prevent PBC recurrence 5

Gallstone Dissolution

  • Dosing: 8-10 mg/kg/day in 2-3 divided doses 3
  • Patient selection: Radiolucent, uncalcified stones <20 mm diameter; floating stones have 50% dissolution rate 3
  • Monitoring: Ultrasound at 6-month intervals; if no partial dissolution by 12 months, discontinue therapy 3
  • Duration: Continue until complete dissolution confirmed on repeat ultrasound 1-3 months after apparent dissolution 3

Gallstone Prevention During Rapid Weight Loss

  • Dosing: 600 mg/day (300 mg twice daily) 3
  • Indication: Patients undergoing rapid weight loss, particularly after bariatric surgery 6
  • Duration: 6 months following laparoscopic sleeve gastrectomy per ASMBS guidelines 6
  • Evidence: Significantly reduces need for cholecystectomy (8.9% vs 15.8%) and ERCP (0.3% vs 2.5%) 6

Conditional/Limited Evidence Indications:

Primary Sclerosing Cholangitis (PSC)

  • Current recommendation: NOT recommended as standard therapy 7
  • Critical caveat: High-dose UDCA (28-30 mg/kg/day) is associated with WORSE outcomes and increased mortality 8, 7, 2, 9
  • Maximum safe dose: Do not exceed 20 mg/kg/day if used 8, 10
  • Exception: Consider corticosteroids plus immunosuppressants for PSC/autoimmune hepatitis overlap syndrome 7

Parenteral Nutrition-Associated Cholestasis (PNAC)

  • Dosing: 10-30 mg/kg/day in children; 10-15 mg/kg/day in adults, divided into 2-3 doses 11
  • Evidence level: Limited to case reports and small studies; may improve biochemical parameters 11
  • Limitation: May be ineffective in short bowel syndrome or resected terminal ileum due to reduced absorption 11

Administration Instructions

Optimal timing: Bedtime administration reduces minimum effective dose compared to mealtime dosing (8.4 mg/kg/day vs 10 mg/kg/day for equivalent effect) 12

Dosing by indication:

  • PBC: 13-15 mg/kg/day divided BID-TID
  • Gallstone dissolution: 8-10 mg/kg/day divided BID-TID
  • Gallstone prevention: 300 mg BID (fixed dose)
  • PNAC: 10-30 mg/kg/day (pediatric); 10-15 mg/kg/day (adult)

Common dosing error: Approximately one-third of PBC patients in the UK are underdosed; over one-third of partial responders become responders when dose is optimized to recommended levels 4

Monitoring Recommendations

For PBC:

  • Baseline: Liver function tests (bilirubin, alkaline phosphatase, ALT, AST), IgM, lipid profile
  • Follow-up: Assess biochemical response at 12 months; continue monitoring liver and renal function tests regularly 5, 1
  • Response criteria: Near-normalization of alkaline phosphatase at 1 year indicates adequate response 4
  • Partial responders: Verify correct dosing (13-15 mg/kg/day); consider dose adjustment before adding second-line therapy 4

For gallstone dissolution:

  • Ultrasound at 6-month intervals during first year 3
  • If no partial dissolution by 12 months, discontinue (success unlikely) 3
  • After apparent dissolution, confirm with repeat ultrasound in 1-3 months 3
  • Monitor for recurrence: up to 50% recur within 5 years; serial ultrasounds recommended 3

For post-bariatric surgery:

  • Clinical assessment for biliary symptoms during 6-month prophylaxis period 6

Safety Profile and Adverse Effects

Generally well-tolerated: Serious adverse events are not significantly different from placebo (13.5% vs 15.6%) 1

Common side effects:

  • Dose-dependent diarrhea (most common) 13
  • Nausea (18.1% report as barrier to compliance) 6
  • Non-serious adverse events: 4.2% vs 2.8% placebo 1

Cost barriers: 45.4% of patients report cost as barrier to compliance 6

Pregnancy and lactation: Confirmed safe for use; excellent tolerability profile 13

Does NOT improve: Pruritus or fatigue in PBC patients 2, 1

Critical Clinical Pitfalls

  1. PSC high-dose toxicity: Never exceed 20 mg/kg/day in PSC; doses of 28-30 mg/kg/day cause increased mortality 8, 7, 2

  2. Underdosing in PBC: Weight-based dosing is essential; fixed low doses lead to treatment failure 4

  3. Premature discontinuation: Continue UDCA in PBC even with persistent alkaline phosphatase elevation—survival benefit persists 1

  4. Inappropriate patient selection for gallstone dissolution: Calcified stones, stones >20 mm, or non-visualizing gallbladder predict failure 3

  5. Absorption issues: Reduced efficacy in short bowel syndrome or terminal ileum resection due to impaired absorption 11

References

Research

Cost effectiveness of using ursodeoxycholic acid to treat primary biliary cholangitis.

British journal of hospital medicine (London, England : 2005), 2018

Research

Best-buy regimen of ursodeoxycholic acid for patients with gallstones.

Scandinavian journal of gastroenterology, 1991

Research

Bile acids in the treatment of hepatobiliary diseases: rational use of UDCA.

Ceska a Slovenska farmacie : casopis Ceske farmaceuticke spolecnosti a Slovenske farmaceuticke spolecnosti, 2026

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.